Effect of Metformin on Healthy Live Birth in Women With Prediabetes

Exclusion Criteria8

• Women who are diagnosed with diabetes according to the ADA criteria11,12, which is meeting one of the following criteria: fasting plasma glucose ≥7.0mmol/L, 2-h plasma glucose during 75-g OGTT ≥11.1mmol/L, HbA1c≥6.5%, or a random plasma glucose≥11.1mmol/L.
• Women who are taking medicine that interfere with glucose metabolism, such as metformin, oral anti-diabetic agents (sulfonylureas, glinides, thiazolidinediones, α-glycosidase inhibitors, GLP-1 receptor agonist, etc.), weight loss drugs (i.e.orlistat, etc.), glucocorticoids, and growth hormones within 2 months before enrollment.
• Women with un-corrected hyperthyroidism or hypothyroidism.
• Women with congenital or acquired abnormal uterine cavity including septate uterus, unicornous uterus, uterus duplex, and intrauterine adhesions.
• Women with a diagnosis of adenomyosis.
• Women with untreated hydrosalpinx.
• Women who plan to undergo PGT-SR or PGT-M.
• Women with major medical comorbidities, such as known liver disease, known renal disease, or known significant anemia.